Sophia Genetics SA
SOPH4.370USD
-0.370-7.81%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
296.49MMarket Cap
LossP/E TTM
More Details of Sophia Genetics SA Company
Sophia Genetics SA is a Switzerland-based company engaged in the software publishing sector. The Company offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The Company has offices in Switzerland, France and the United Kingdom and operates worldwide.
Sophia Genetics SA Info
Ticker SymbolSOPH
Company nameSophia Genetics SA
IPO dateJul 23, 2021
CEODr. Jurgi Camblong, Ph.D.
Number of employees423
Security typeOrdinary Share
Fiscal year-endJul 23
AddressLa Piece 12
CityROLLE
Stock exchangeNASDAQ Global Select Consolidated
CountrySwitzerland
Postal code1180
Phone41216941060
Websitehttps://www.sophiagenetics.com/
Ticker SymbolSOPH
IPO dateJul 23, 2021
CEODr. Jurgi Camblong, Ph.D.
Company Executives of Sophia Genetics SA
Name
Name/Position
Position
Shareholding
Change
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+7.89%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+12.21%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-4.26%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+25.98%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+79.72%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+108.22%
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
60.38K
+51.32%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer and Chief Product Officer
Chief Medical Officer and Chief Product Officer
39.60K
-5.14%
Mr. George A. Cardoza
Mr. George A. Cardoza
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jean-Michel Cossiery, Ph.D.
Mr. Jean-Michel Cossiery, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+7.89%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+12.21%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-4.26%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+25.98%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+79.72%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+108.22%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Rest of EMEA
5.78M
31.53%
Italy
2.78M
15.19%
France
2.72M
14.82%
United States
2.66M
14.52%
Spain
1.63M
8.90%
Other
2.75M
15.04%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Nov 4
Updated: Tue, Nov 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
Other
61.13%
Shareholders
Shareholders
Proportion
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
Other
61.13%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
16.14%
Venture Capital
13.13%
Family Office
10.40%
Investment Advisor
8.46%
Individual Investor
6.46%
Hedge Fund
1.43%
Bank and Trust
0.45%
Pension Fund
0.14%
Research Firm
0.03%
Other
43.35%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
75
26.89M
39.79%
-8.96M
2025Q2
89
36.69M
54.29%
-200.15K
2025Q1
93
36.63M
54.82%
-389.48K
2024Q4
93
32.50M
49.36%
-965.83K
2024Q3
91
34.60M
52.08%
+657.87K
2024Q2
92
32.44M
48.93%
+1.33M
2024Q1
93
31.91M
48.51%
+375.11K
2023Q4
91
30.61M
46.76%
-676.23K
2023Q3
91
30.34M
46.61%
-4.34M
2023Q2
90
31.34M
48.19%
-3.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alychlo NV
6.99M
10.35%
--
--
Feb 15, 2025
Generation Investment Management LLP
6.79M
10.05%
--
--
Jun 30, 2025
aMoon Fund
5.51M
8.15%
+577.36K
+11.70%
Feb 15, 2025
Akre Capital Management, LLC
3.72M
5.5%
+1.48M
+66.22%
Jun 30, 2025
Balderton Capital (UK) LLP
3.36M
4.97%
--
--
Feb 15, 2025
Camblong (Jurgi)
2.65M
3.93%
+194.16K
+7.89%
Feb 15, 2025
Banque Pictet & Cie S.A.
2.21M
3.27%
-2.76K
-0.12%
Jun 30, 2025
Principal Global Investors (Equity)
1.40M
2.07%
+15.15K
+1.09%
Jun 30, 2025
Millennium Management LLC
584.42K
0.86%
+45.30K
+8.40%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Health Innovation Active ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Health Innovation Active ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
